Accounts Receivable

9 Months Ended

Sep. 30, 2019

Receivables [Abstract]

Accounts Receivable

Accounts Receivable

During the three months ended September 30, 2019, the Company recorded $20.5 million of royalty revenue, which includes the final milestone payment due to the Company of $13.5 million, as sales of NARCAN® exceeded $200 million during the nine months ended September 30, 2019. As of September 30, 2019, the Company had accounts receivable of $16.1 million, which represents the $20.5 million of revenue, offset by $4.5 million for the final license fees (see Note 7), and $100 thousand receivable due from BARDA. As of December 31, 2018 the Company had accounts receivable of $4.5 million, which related to royalty revenue from the sales of NARCAN®.